Sutro Biopharma (STRO) Preferred Stock Liabilities (2017 - 2018)
Sutro Biopharma (STRO) reported Preferred Stock Liabilities of $187.2 million for Q3 2018, up 82.67% sequentially from $102.5 million in Q4 2017.
Sutro Biopharma (STRO) Preferred Stock Liabilities (2017 - 2018) Analysis & Trends
Sutro Biopharma (STRO) has 2 years of Preferred Stock Liabilities data on file, last reported at $187.2 million in Q3 2018.
- For the quarter ending Q3 2018, Preferred Stock Liabilities changed N/A year-over-year to $187.2 million; the trailing twelve-month figure through Sep 2018 stood at $187.2 million (changed N/A YoY), and the FY2017 full-year result was $102.5 million, changed 0.0% from the prior year.
- Preferred Stock Liabilities advanced to $187.2 million in Q3 2018, from $102.5 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $187.2 million in Q3 2018 to a low of $102.5 million in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Sutro Biopharma | 192.86 Mn | 51.43 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 187.25 Mn |
| Dec 31, 2017 | 102.51 Mn |